
Argenica Therapeutics Ltd
ASX:AGN

Intrinsic Value
The intrinsic value of one
AGN
stock under the Base Case scenario is
0.03
AUD.
Compared to the current market price of 0.725 AUD,
Argenica Therapeutics Ltd
is
Overvalued by 96%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Argenica Therapeutics Ltd
Fundamental Analysis


Revenue & Expenses Breakdown
Argenica Therapeutics Ltd
Balance Sheet Decomposition
Argenica Therapeutics Ltd
Current Assets | 15.4m |
Cash & Short-Term Investments | 15.1m |
Receivables | 262.3k |
Other Current Assets | 69.6k |
Non-Current Assets | 1k |
Intangibles | 1k |
Free Cash Flow Analysis
Argenica Therapeutics Ltd
AUD | |
Free Cash Flow | AUD |
Earnings Waterfall
Argenica Therapeutics Ltd
Revenue
|
413.8k
AUD
|
Operating Expenses
|
-5.9m
AUD
|
Operating Income
|
-5.5m
AUD
|
Other Expenses
|
245k
AUD
|
Net Income
|
-5.3m
AUD
|
AGN Profitability Score
Profitability Due Diligence
Argenica Therapeutics Ltd's profitability score is 36/100. The higher the profitability score, the more profitable the company is.

Score
Argenica Therapeutics Ltd's profitability score is 36/100. The higher the profitability score, the more profitable the company is.
AGN Solvency Score
Solvency Due Diligence
Argenica Therapeutics Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Score
Argenica Therapeutics Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AGN Price Targets Summary
Argenica Therapeutics Ltd
Dividends
Current shareholder yield for AGN is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
AGN
stock under the Base Case scenario is
0.03
AUD.
Compared to the current market price of 0.725 AUD,
Argenica Therapeutics Ltd
is
Overvalued by 96%.